Antibiotic Resistance Statistics in US 2026 | Key Facts

What Is Antibiotic Resistance?

Antibiotic resistance (AR) — also called antimicrobial resistance (AMR) — occurs when bacteria, fungi, or other microorganisms develop the ability to defeat the drugs designed to kill them. When a germ becomes resistant, antibiotics that once cured infections no longer work, meaning infections last longer, spread more easily, require stronger and more expensive medications, and kill more people. Resistance is a natural biological process accelerated by the overuse and misuse of antibiotics in human medicine, agriculture, and the environment. When bacteria are repeatedly exposed to antibiotics — including when people take them unnecessarily for viral infections like colds and flu, or when livestock are treated with the same classes of drugs used in human medicine — the bacteria most capable of surviving exposure pass on their resistance traits, creating stronger and more dangerous successive generations. The Centers for Disease Control and Prevention (CDC) classifies 18 organisms as antimicrobial-resistant threats, organized into three tiers: urgent, serious, and concerning, plus a Watch List of emerging threats. In 2026, the CDC is releasing an updated assessment covering estimates for at least 19 AMR threats — the first comprehensive update since the landmark 2019 AR Threats Report — in a new electronic format, a release that is anticipated to show burden levels significantly above the 2019 baseline due to the lasting impact of the COVID-19 pandemic.

In 2026, antibiotic resistance in the United States is operating at a burden that has not fully recovered to its pre-pandemic trajectory. More than 2.8 million antimicrobial-resistant infections occur in the US each year, and more than 35,000 people die as a result, according to CDC’s 2019 AR Threats Report. When Clostridioides difficile (C. diff) — a bacterium that is not typically resistant but is associated with antibiotic use and causes deadly diarrhea — is added, the US toll exceeds 3 million infections and 48,000 deaths annually. These figures represent the pre-pandemic baseline established in 2019. The most current CDC data — the 2021–2022 update published in July 2024 — confirms that six bacterial antimicrobial-resistant hospital-onset infections increased by a combined 20% during the COVID-19 pandemic compared to the pre-pandemic period, peaking in 2021 and remaining above pre-pandemic levels in 2022. And reported clinical cases of Candida auris — a multidrug-resistant yeast that spreads in healthcare facilities — increased nearly five-fold from 2019 to 2022. The US is fighting antibiotic resistance from a position where COVID-19 undid years of hard-won progress, and where the pipeline of new antibiotics remains dangerously thin relative to the pace at which resistance is evolving.

Interesting Antibiotic Resistance Facts in the US 2026

Source: CDC AR Facts & Stats (updated February 4, 2025), CDC AR Threats Report 2019, CDC AR Threats Update 2021–2022 (published July 2024), National Estimates of Healthcare Costs / Oxford Academic (January 2021), StatPearls Antibiotic Resistance (updated January 31, 2026), The Lancet Global AMR 2019 analysis, media.market.us AMR Statistics (January 30, 2026), NCBI Bookshelf — Health & Economic Burden of Resistance

The two numbers that anchor the entire US antibiotic resistance debate — 2.8 million annual infections and 35,000 annual deaths — come from the CDC’s 2019 AR Threats Report and were the most comprehensive national estimates available until the partial update in July 2024 and the full 2026 report now due from CDC covering at least 19 threats. What the July 2024 update confirmed is that those already alarming 2019 baseline figures are now an understatement of the current burden. The COVID-19 pandemic resulted in longer hospital stays for hospitalized patients, challenged the implementation of infection prevention and control practices, and increased inappropriate antibiotic use — and six key resistant pathogens remained above pre-pandemic levels in 2022. The healthcare cost figure of more than $4.6 billion annually — covering just six of the 18 monitored AR threats — is itself widely acknowledged to be a conservative lower bound; it captures direct inpatient treatment costs but does not fully account for lost productivity, prolonged outpatient care, long-term disability, or the indirect costs of failed surgeries, cancer chemotherapy, and organ transplants that depend on effective antibiotics to proceed safely.

The pre-COVID trajectory offered genuine hope: dedicated prevention and infection control efforts reduced deaths from antimicrobial-resistant infections by 18% overall and by nearly 30% in hospitals between approximately 2012 and 2019. That progress — achieved through investment in antibiotic stewardship programs, hospital infection control infrastructure, and expanded surveillance — was substantially reversed in a single year. The 15% increase in both resistant hospital-onset infections and deaths in 2020 documented in the CDC’s COVID Impact Special Report stands as one of the most severe documented setbacks to a public health program in modern US history. By 2022, most of the six tracked resistant hospital pathogens remained elevated above pre-pandemic levels, with the exception of MRSA — the one pathogen for which pre-pandemic stewardship efforts had been most deeply embedded in hospital culture. The full scope of the pandemic’s damage will become clearer when the 2026 CDC AR Threats Report is published.

AR Infection & Death Statistics in the US 2026

Source: CDC AR Threats in the United States 2019 (national estimates), CDC AR Facts & Stats (updated Feb 4, 2025), CDC AR Threats Update 2021–2022 (published July 2024), StatPearls Antibiotic Resistance (updated January 31, 2026), media.market.us AMR Statistics (January 30, 2026), NCBI PMC / Oxford Academic CID national cost study

More than 2.8 million antibiotic-resistant infections occur in the United States each year, and more than 35,000 people die as a result. In addition, nearly 223,900 people in the United States required hospital care for C. difficile and at least 12,800 people died. The pathogen-by-pathogen data in this table illustrates the extraordinary diversity of the AR threat — it is not one disease but an umbrella of dozens of distinct clinical problems, each requiring different treatments, each driven by different resistance mechanisms, and each presenting different challenges for clinicians. MRSA — once the defining face of the antibiotic resistance crisis — is the one pathogen where pandemic-era gains were partially maintained, in part because MRSA stewardship became so deeply embedded in hospital culture and protocol over the preceding decade that the COVID-era disruptions did not fully undo them. In the United States, approximately 80,461 invasive MRSA infections occur annually, resulting in around 11,285 deaths.

The most alarming trend in 2025–2026 is not in the bacteria that have been tracked for decades but in the fungi. Candida auris can cause invasive infections particularly in patients who are already critically ill — individuals with central venous catheters, recent surgeries, or long-term antibiotic use — and can enter the bloodstream, leading to sepsis, organ failure, and death, with mortality rates associated with bloodstream infections as high as 30–60%. In late 2025, a long-term acute care hospital in the Midwest experienced a sustained C. auris outbreak despite adherence to CDC-recommended protocols, with genomic analysis revealing a new clade with mutations subtle enough to reduce disinfectant efficacy and escape traditional PCR detection primers. In some parts of the world, CRE rates in healthcare settings can exceed 50%, and CRE infections carry high mortality rates ranging from 40% to over 50% in some studies — a case fatality rate that rivals the most feared infectious diseases in human history.

Antibiotic Resistance Healthcare Cost Statistics in the US 2026

Source: CDC Healthcare Cost Study (University of Utah collaboration), Oxford Academic / Clinical Infectious Diseases national cost estimates (January 2021), PMC / VA elderly MDR cost study, BMJ Global Health WHO modeling study (June 19, 2025), PLOS ONE economic burden systematic review (May 2023), NCBI Bookshelf — Health & Economic Burden, media.market.us AMR Statistics (January 30, 2026)

Six of the 18 most alarming antibiotic resistance threats cost the US more than $4.6 billion annually in direct healthcare treatment costs, according to a CDC-led collaborative study with the University of Utah School of Medicine. That figure covers only the treatment costs of six pathogens in inpatient settings — it excludes outpatient treatment costs, the indirect costs of lost workdays and long-term disability, and the systemic economic cost of the procedures that become impossible when antibiotics fail. When MRSA alone carries a $1.2 billion annual community-onset treatment cost and ESBL infections cost another $752 million — and these are just two of six measured pathogens, measured only in hospitals — the true all-in US cost of antibiotic resistance almost certainly runs into the tens of billions of dollars annually. A newly published BMJ Global Health modeling study released June 19, 2025, conducted by researchers from the London School of Hygiene & Tropical Medicine in collaboration with WHO, estimated that antibiotic resistance was associated with nearly $700 billion in hospital costs globally in 2019 alone, with an additional $193 billion in productivity losses from excess deaths attributable to AMR.

The cost-per-case data from the PLOS ONE systematic review published in May 2023 — which analyzed 29 studies across high-income countries — illustrates the financial depth of the problem for individual patients and hospitals. Attributable costs of resistant infections ranged from negative values for some MRSA comparisons (where community-acquired MRSA is often susceptible to cheaper second-line drugs) to more than $29,289 additional cost per case for Vancomycin-resistant Enterococcus infections compared to susceptible equivalents. The extended length of hospital stay associated with resistant infections — 7.2 additional days in tertiary care settings — represents both a direct cost and a systemic capacity bottleneck: every bed occupied for an extra week by a patient with a treatment-resistant infection is a bed unavailable for elective surgical cases, cancer treatments, and other scheduled care. The cumulative effect of this bottleneck, multiplied across millions of resistant infections annually, represents a structural drag on the entire US healthcare system that is vastly larger than the direct treatment cost figures capture.

Antibiotic Prescribing & Misuse Statistics in the US 2026

Source: CDC Antibiotic Prescribing and Use data, media.market.us AMR Statistics (January 30, 2026), WHO Global Antimicrobial Resistance Surveillance System, ASPE National Action Plan Progress Report FY2022, CDC COVID-19 U.S. Impact on Antimicrobial Resistance Special Report 2022

In the United States, about 30% of antibiotics prescribed in outpatient settings are unnecessary. This figure — documented by CDC surveillance and replicated in multiple peer-reviewed studies — means that nearly one in three antibiotic prescriptions written in American clinics, urgent care centers, and emergency rooms is providing no clinical benefit to the patient while actively contributing to the very resistance crisis that makes those same antibiotics less effective for everyone. The problem is compounded in the global context: the median prevalence of inappropriate antibiotic prescriptions in primary care globally is 52% — meaning more than half of all antibiotic prescriptions written in primary care settings worldwide, in the most comprehensive systematic review available, were deemed unnecessary or inappropriate. The consequence plays out in the clinical data: the failure rate of antibiotics commonly used to treat urinary tract infections caused by E. coli increased from 5.7% in 2011 to 13.9% in 2017 — a near-tripling of treatment failure rates in just six years, driven directly by selection pressure from inappropriate prescribing.

The agricultural dimension of antibiotic misuse is an underappreciated driver of the US resistance burden. Antibiotics in the same classes used to treat human infections — tetracyclines, penicillins, macrolides — are administered to livestock in the US at enormous scale, both for disease treatment and historically for growth promotion. Resistance genes that develop in farm animal bacteria can transfer to human pathogens through the food chain, farm workers, and environmental contamination of soil and waterways. The CDC’s One Health framework — which explicitly links human health, animal health, and environmental health as a unified system for combating AMR — underpins the National Antimicrobial Resistance Monitoring System (NARMS), a collaboration among the FDA, CDC, and USDA that tracks antimicrobial susceptibility in bacteria from humans, retail meats, and food animals. The FY2022 National Action Plan Progress Report noted that the COVID-19 pandemic’s disruption of NARMS data collection created surveillance gaps that are only now being filled in 2025 and 2026.

Top Antibiotic Resistance Threats in the US 2026

Source: CDC AR Threats in the United States 2019 (primary national estimates), CDC AR Facts & Stats (updated February 4, 2025), CDC AR Threats Update 2021–2022 (July 2024), StatPearls Antibiotic Resistance (January 31, 2026), Drugs.com AR Top 10 (updated January 2025), CIDRAP AMR Benchmark 2026 (March 2026)

The five URGENT threats designated by CDC represent the pathogens where the combination of existing resistance mechanisms, limited treatment options, and healthcare impact creates the most immediate risk to patient safety. Urgent threats to human health include Carbapenem-resistant Acinetobacter, Clostridium difficile, Candida auris, Carbapenem-resistant Enterobacteriaceae, and drug-resistant Neisseria gonorrhoeae. What unites these five is that each represents a domain where currently available medical tools are insufficient or deteriorating: CRE infections have case fatality rates of 40–50% partly because the antibiotics of last resort — carbapenems — no longer work against them, leaving clinicians with older, more toxic alternatives; C. auris in its most dangerous strains is pan-resistant, meaning no antifungal drug in any of the three major classes provides effective treatment; drug-resistant gonorrhea has progressively eliminated every first-line treatment option over the past 40 years and is now threatening to become incurable in its most resistant strains.

The drug-resistant gonorrhea situation deserves particular attention as the area where the most significant recent clinical progress has been made. The FDA has recently approved two new antibiotics — zoliflodacin and gepotidacin — for uncomplicated gonorrhea infections, which are the first new oral treatment options for gonorrhea in decades. These approvals — highlighted in the 2026 Antimicrobial Resistance Benchmark Report released by the Access to Medicine Foundation in March 2026 — arrived at a critical moment, as gonorrhea resistance to azithromycin, fluoroquinolones, and even cephalosporins has rendered much of the previous treatment arsenal unreliable. However, the broader pipeline picture is sobering: since the last AMR Benchmark report in 2021, the number of pipeline candidates from large research-based companies has fallen by 35%, from 92 to 60, with much of the remaining antibiotic research driven by just three companies — GSK, Pfizer, and Shionogi.

Candida Auris Statistics in the US 2026

Source: CDC Antimicrobial Resistance Facts & Stats (updated February 4, 2025), CDC AR Threats Update 2021–2022 (July 2024), MedicalRealities.com — Candida Auris: The Emerging Multidrug-Resistant Fungus (May 23, 2025), StatPearls (updated January 31, 2026), CDC AR Investment Map (January 28, 2026)

Candida auris is a multidrug-resistant fungus, and cases have increased 5-fold since 2019, making it the fastest-growing tracked antimicrobial-resistant threat in the United States. What makes C. auris uniquely dangerous is the convergence of four characteristics that no other tracked pathogen shares simultaneously: it spreads rapidly between patients in healthcare settings through surface contact; it persists on hospital surfaces and equipment even after standard cleaning protocols; it is frequently misidentified by standard laboratory tests as less dangerous Candida species, causing critical delays in appropriate treatment and isolation; and it can become resistant to all three major classes of antifungal medications — azoles, echinocandins, and polyenes — leaving clinicians with no effective treatment option. The late 2025 Midwest hospital outbreak — in which a new genomic clade with mutations sufficient to reduce disinfectant efficacy and evade standard PCR detection primers emerged despite full CDC-protocol compliance — represents precisely the nightmare scenario that AMR researchers have been warning about for years.

The years 2025 and 2026 have been pivotal in the ongoing story of Candida auris. Despite widespread awareness and more robust infection control practices in many high-income countries, C. auris continues to thrive in unexpected ways — often adapting faster than healthcare systems can respond. Outbreaks reported in 2025 in parts of Southeast Asia and Central Europe involved pan-resistant strains — organisms with no susceptibility to any of the three major antifungal classes — triggering temporary ICU closures, emergency response coordination, and in some cases, international reporting under WHO’s revised IHR protocols. A multi-center case study published in early 2026 from South America described an outbreak that began with a single colonized patient transferred between facilities and affected over 30 individuals across four hospitals within six weeks — a transmission pattern that underscores why C. auris is now classified as a global health security threat, not merely a clinical infection control problem.

New Antibiotics Pipeline Statistics in the US 2026

Source: CIDRAP — “Report Highlights Spots of Progress” (March 2026, reviewing 2026 AMR Benchmark Report by Access to Medicine Foundation), Access to Medicine Foundation 2026 AMR Benchmark Report (released March 2026), Lancet Microbe WHO pipeline analysis (March 2025), ASPE National Action Plan Progress Report FY2022, Drugs.com Antibiotic Resistance Top 10 (January 2025)

The 2026 AMR Benchmark Report, released by the Access to Medicine Foundation and reviewed by CIDRAP in March 2026, highlights the recent FDA approvals of zoliflodacin and gepotidacin for uncomplicated gonorrhea infections — the first new oral treatment options for gonorrhea in decades, arriving at a time when gonorrhea cases are rising and current treatment options are becoming less effective. These two approvals represent meaningful clinical progress, but they are a narrow bright spot against a broader pipeline crisis. The 35% decline in large-pharma antibiotic pipeline candidates from 92 in 2021 to 60 in 2026 tells the structural story: antibiotics are not economically attractive to large pharmaceutical companies because they are prescribed in short courses, patients recover and stop taking them, and stewardship programs explicitly limit their use — the exact opposite of the commercial model that justifies the $1–2 billion cost of bringing a drug through clinical trials and regulatory approval.

The consequence is a two-tier pipeline: a handful of large companies maintaining programs largely for reputational or strategic reasons, and a set of small and medium enterprises carrying disproportionate innovation burden — four of the seven highlighted products in the 2026 AMR Benchmark Report originated from SMEs. These companies, which don’t have a large global reach and often have to fight for financing just to get their products through clinical trials, are “punching above their weight”, according to the report’s researchers. The CARB-X program — funded by BARDA with up to $300 million over ten years — is the primary US government mechanism for keeping this preclinical pipeline alive. But it faces the same fundamental challenge: even if a new antibiotic successfully completes development, the economics of the antibiotic market often make it commercially unviable to manufacture and distribute at the scale needed, creating a market failure that no amount of scientific innovation can solve without parallel policy reform to create viable commercial incentives for antibiotic development.

Global Context for US Antibiotic Resistance Statistics in 2026

Source: The Lancet global AMR analysis (2022), BMJ Global Health WHO modeling study published June 19, 2025, StatPearls Antibiotic Resistance (updated January 31, 2026), media.market.us AMR Statistics (January 30, 2026), WHO Global Antimicrobial Resistance Surveillance Report 2025, CDC AR Threats 2019 and update 2021–2022

The global scale of antibiotic resistance in 2026 places the US burden in its proper context. AMR is an urgent global public health threat, killing at least 1.27 million people worldwide and associated with nearly 5 million deaths in 2019, according to a report released in The Lancet. The US’s 35,000 annual AR deaths represent approximately 2.8% of the global directly-attributed toll — significant for a single high-income nation, and a figure that underscores how deeply entrenched this problem is even in countries with advanced healthcare infrastructure, comprehensive surveillance, and robust infection control programs. The sobering arithmetic of the 2050 forecast — 10 million annual deaths globally if the trajectory goes unaddressed — would make antibiotic resistance the leading cause of death globally, surpassing current leading killers including cancer and cardiovascular disease. The economic parallel is equally staggering: $2 trillion to $100 trillion in cumulative global economic losses by 2050 — a range whose width reflects not uncertainty about whether the losses will be catastrophic, but uncertainty about precisely how catastrophic the failure to act will prove.

In 2026, the CDC will release estimates for at least 19 antimicrobial resistance threats and an update on the US burden of antimicrobial resistance in a new electronic format — the first comprehensive update since the 2019 AR Threats Report. This report, anticipated later in 2026, will be the most complete picture of the current US AMR burden available and is expected to confirm that pandemic-era setbacks have added meaningfully to the infection and death toll above the 2019 baseline. Global surveillance efforts are expanding in response to this threat. The WHO Global Antimicrobial Resistance Surveillance System, launched in 2015, provides standardized international data on antimicrobial resistance trends to inform policy. In 2024, the United Nations General Assembly reaffirmed worldwide commitments to stewardship, innovation, and equitable access to effective antimicrobials. The scientific and policy response to AMR in 2026 is broader and more coordinated than at any point in history — and yet it still lags the pace at which resistance is evolving in the microbial world.

Disclaimer: The data reports published on The Global Files are sourced from publicly available materials considered reliable. While efforts are made to ensure accuracy, no guarantees are provided regarding completeness or reliability. The Global Files is not liable for any errors, omissions, or damages resulting from the use of these reports.